Overview

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers

Status:
RECRUITING
Trial end date:
2025-02-10
Target enrollment:
Participant gender:
Summary
This is a phase 1, randomized, First in Human (FIH), double-blinded, placebo-controlled study to assess the safety, tolerability, and PK of RSN0402 in healthy volunteers. A total of about 72 participants are expected to be enrolled.
Phase:
PHASE1
Details
Lead Sponsor:
Shenzhen Resproly Biopharmaceutical Co., Ltd
Collaborator:
Resproly Australia Pty Ltd